Bruker Announces Acquisition of ACQUIFER Imaging GmbH
Adding Big-Data Management and High-Content Screening Solutions for Bioimaging Applications
HEIDELBERG, Germany – January 5, 2023 – Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of ACQUIFER Imaging GmbH, a pioneer in big-data management solutions for bioimaging and high-content microscopy. This acquisition adds high-performance on-premise processing, secure storage and networking technology that complements Bruker’s advanced fluorescence microscopy imaging products, such as light-sheet and super-resolution microscopy products, which generate high information content.
ACQUIFER's flagship HIVE™ data management systems feature a fast backbone for very high data collection speed and multicore, multi-GPU processing, as well as scalable plug-and-play storage modules up to the petabyte (PB) range. The acquisition also includes the innovative IM04 Imaging Instrument, a robust, automated high-content imaging system for reproducible phenotypic screening of cells, whole organisms, and organoids. Financial details of the transaction were not disclosed.
“Cutting-edge bioresearch often requires high-performance big-data management, which HIVE can offer,” said Dr. Peter Zehetmayer, COO and Director for Sales & Marketing at ACQUIFER. “In addition, our IM04 system expands Bruker’s fluorescence microscopy portfolio into the high-content screening arena. As part of Bruker, we anticipate the ability to greatly expand the reach of our scientific computing and imaging technologies worldwide.”
“The ACQUIFER HIVE system was developed to keep up with the ever-increasing amount of data that life science research can generate. In combination with Bruker’s fluorescence microscopy platforms, including our light-sheet microscopy instrumentation, we can now offer a holistic solution for advanced imaging and big-data management,” added Dr. Malte Wachsmuth, Managing Director and Head of Applications, Support & Service for Bruker’s Luxendo Light Sheet Microscopy Business. “We also are very excited about augmenting our support for organoid, stem cell, and developmental biology research with the IM04 high-content screening system.”
Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.